医学
重症监护医学
疾病
肺病
肺结核
肺病
分枝杆菌复合群
免疫学
肺
内科学
病理
作者
Chiqing Ying,L. Zhang,Xuehang Jin,Dexiang Zhu,Wei Wu
标识
DOI:10.1016/j.diagmicrobio.2024.116254
摘要
The prevalence of Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) is increasing worldwide. The advancement in molecular diagnostic technology has greatly promoted the rapid diagnosis of NTM-PD clinically, and the pathogenic strains can be identified to the species level through molecular typing, which provides a reliable basis for treatment. In addition to the well-known PCR and mNGS methods, there are numerous alternative methods to identify NTM to the species level. The treatment of NTM-PD remains a challenging problem. Although clinical guidelines outline several treatment options for common NTM species infections, in most cases, the therapeutic outcomes of these drugs for NTM-PD often fall short of expectations. At present, the focus of research is to find more effective and more tolerable NTM-PD therapeutic drugs and regimens. In this paper, the latest diagnostic techniques, therapeutic drugs and methods, and prevention of NTM-PD are reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI